Although p16INK4a(CDKN2a) promoter methylation has been reported in advanced stage Wilms' tumours (Arcellana-Panlilio et al, 2000), this trend was not significant in our series, and to date no specific clinicopathological features have been associated with SLIT2, CASP8 and RASSF1A methylation. This evidence concerns the gene CDKN2A and Wilms tumor.